Jenne Kyle 4

4 · IONIS PHARMACEUTICALS INC · Filed Apr 17, 2026

AI-generated summary of this filing

Updated Apr 17, 2026

Ionis (IONS) EVP Jenne Kyle Receives RSUs, Sells Shares

What Happened

Jenne Kyle, EVP & Chief Global Product Strategy Officer at Ionis Pharmaceuticals, had 12,226 Restricted Stock Units (RSUs) vest on 2026-04-15 and the RSUs converted into 12,226 shares (reported as acquired at $0.00). Following vesting, 4,902 of those shares were sold on 2026-04-16 in an automatic sale to cover tax withholding, yielding proceeds of $368,488 at a weighted average price of $75.17. The sale prices ranged from $75.06 to $75.26.

Key Details

Transaction dates: RSU vesting/conversion 2026-04-15; sale to cover taxes 2026-04-16; Form 4 filed 2026-04-17 (timely).
Acquired: 12,226 shares upon RSU vesting (reported at $0.00) — see footnotes on RSU treatment.
Sold: 4,902 shares; weighted avg price $75.17; total proceeds $368,488. Sales occurred across multiple trades at $75.06–$75.26.
Purpose of sale: automatic sale to cover required tax withholding under the 2011 Equity Incentive Plan (footnote).
Footnotes: RSUs represent a contingent right to one share and vest in four equal annual installments; upon vesting they are paid in shares or cash per the plan. The filer can provide a price-by-price breakdown on request.
Shares owned after the transaction: not specified in the filing.

Context

These were RSU vesting and an automatic tax-withholding sale (not an open-market investment decision). For derivative transactions: RSUs are not option exercises for cash gain — they are grants that converted into shares upon vesting, and a portion was sold immediately to satisfy tax obligations. This pattern is common and typically routine for executives receiving equity compensation.

Form 4

Period: 2026-04-15

EVP, Chf GL Pdt Str Ofcr

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-15+12,226→ 28,615 total
Sale
Common Stock
[F2][F3]
2026-04-16$75.17/sh−4,902$368,488→ 23,713 total
Exercise/Conversion
Restricted Stock Unit
[F4][F5]
2026-04-15−12,226→ 74,402 total
Exercise: $0.00From: 2026-04-15→ Common Stock (12,226 underlying)

Footnotes (5)

[F1]Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.
[F2]The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.06 to $75.26 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
[F4]Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
[F5]Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

Signature

By: Patrick R. O'Neil, attorney-in-fact For: Kyle Jenne|2026-04-17

1 file